García-Álvarez GA, Elizalde-Valdés VM

Language: Spanish
References: 9
Page: 12-16
PDF size: 99.82 Kb.

ABSTRACT

Introduction: Hypertensive disorders of pregnancy affect approximately 15% of pregnant women and account for almost 18% of all maternal deaths in the world, with an estimated 62 000 to 77 000 deaths per year. Objective: To determine the sensitivity and specificity of the protein/creatinine index and the urine test strip for the diagnosis of significant proteinuria in patients with pre-eclampsia and to compare both tests with the determination of proteinuria in the 24-hour Urine collection considered the gold standard. Method: it was realized a study prospective, transversal and comparative in 74 patients diagnosed with hypertensive disease of pregnancy were collected 24-hour urine, protein/creatinine index and urine dipstick, then the correlation between tests was sought as well as sensitivity and specificity of the protein/creatinine index was determined. Results: A moderate relation was found between both tests compared with the gold standard, with a value of χ² (1) = 7.99, p ‹ 0.05 for the creatinina/protein index and for the urine test strip a value of χ² (1) = 4.17, p ‹ 0.05, coefficient of contingency of 0.31 p ‹ 0.05 and 0.23 p ‹ 0.05 respectively. With a sensitivity of 92% and a specificity of 62% for creatinina/protein index with an area under the curve of 0.75. Conclusion: It found that there is a significant correlation between IPC and R24 for the diagnosis of proteinuria in women with preeclampsia.

REFERENCES

1. Abalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP et al. Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health, 2014; 121 (Suppl 1): 14-21.

2. Organization, World Health. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Switzerland: WHO Library Cataloguing-in-Publication Data, 2011.

3. Secretaría de Salud. Atención integral de la preeclampsia en el segundo y tercer niveles de atención. México: s.n., 2008.

4. Salud, Secretaría de Prevención, diagnóstico y tratamiento de la Preeclampsia en segundo y tercer nivel de atención. México: s.n., 2017.

5. Freyermuth G, Luna M, Muños J. Mortalidad materna en México, centro de investigaciones y estudios superiores en antropología social (CIESAS). México: Observatorio de Mortalidad Materna en México (OMM), 2016.

6. Shreya G, Pranathi L, Kavitha V. Comparison of spot urine protein-creatinine ratio with-24-hour urine protein excretion in women with preeclampsia, Int J Intg Med Sci, 2015; 2 (1): 55-59.

7. Rathindranath R, Teesta B, Proloy M. Evaluation of spot urine protein/creatinine ratio versus 24 hour urine protein in diagnosis of hypertensive disorders of pregnancy. [Documento] Calcuta: IOSR Journal of Dental and Medical Sciences, 2015. e-ISSN: 2279-0853, p-ISSN: 2279-0861; 14 (2): 44-47.

8. Nephrology, International Society of KDIGO 2017 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. s.l.: Kidney International Supplements, 2017; 7 (1).

9. Montañés R, Gràcia S, Pérez D, Martínez A, Bover J. Documento de Consenso. Recomendaciones sobre la valoración de la proteinuria en el diagnóstico y seguimiento de la enfermedad renal crónica, Nefrología, 2011; 31 (3): 331-345.